Drug Trial Radar · NCT01067820
ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation
Last checked: Nov 19, 2026Latest source record: Jun 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
324
Actual
Start
Sep 2011
Primary completion
May 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- Resverlogix CorpIndustry
- Sponsor type
- Industry
- Collaborators
- The Cleveland Clinic
- First posted
- Feb 12, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to characterize the early effects of ApoA-I synthesis with RVX000222 on coronary atherosclerotic disease when administered to patients with coronary artery disease and have a low HDL-C level, as assessed by Intravascular Ultrasound (IVUS) in addition to standard background therapy.
Conditions
- Coronary Artery Disease
Interventions
RVX000222Drug
capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 26 weeks
Placebo RVX000222Drug
capsule, administer with food, twice daily 10-12 hrs apart, 26 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- The nominal change in percent atheroma volume (PAV) from baseline to 26 weeks postrandomization, as determined by intravascular ultrasound (IVUS) within the RVX000222 treated group.Time frame: baseline to 26 weeks postrandomization
Locations
58 sites in 8 countries. Site status is shown where the registry gives one.
Site not named
Buenos Aires, Argentina
Site not named
Buenos Aires, Argentina
Site not named
Córdoba, Argentina
Site not named
Córdoba, Argentina
Site not named
Córdoba, Argentina
Site not named
Córdoba, Argentina
Site not named
Córdoba, Argentina
Site not named
Corrientes, Argentina
Site not named
San Isidro, Argentina
Site not named
La Plata, Buenos Aires, Argentina
Site not named
Brussels, Belgium
Site not named
Charleroi, Belgium
Site not named
Edegem, Belgium
Site not named
Genk, Belgium
Site not named
Brasília, Brazil
Site not named
Cariacica, Brazil
Site not named
Curitiba, Brazil
Site not named
Goiânia, Brazil
Site not named
Porto Alegre, Brazil
Site not named
São Paulo, Brazil
Site not named
São Paulo, Brazil
Site not named
Uberlândia, Brazil
Site not named
Budapest, Hungary
Site not named
Budapest, Hungary
Site not named
Budapest, Hungary
Site not named
Budapest, Hungary
Site not named
Pécs, Hungary
Site not named
Szeged, Hungary
Site not named
Alkmaar, Netherlands
Site not named
Amsterdam, Netherlands
Site not named
Eindhoven, Netherlands
Site not named
Enschede, Netherlands
Site not named
Nijmegen, Netherlands
Site not named
Rotterdam, Netherlands
Site not named
Zwolle, Netherlands
Site not named
Katowice, Poland
Site not named
Warsaw, Poland
Site not named
Warsaw, Poland
Site not named
Moscow, Russia
Site not named
Moscow, Russia
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.